Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free DNTH Stock Alerts

Dianthus Therapeutics (DNTH) Financials

Dianthus Therapeutics logo
$86.16 +0.82 (+0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$86.06 -0.10 (-0.12%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Dianthus Therapeutics

Annual Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.74 -36 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Net Income / (Loss) Continuing Operations		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Pre-Tax Income 		-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Operating Income		 -9.27 -36 -60 -83 -79 -75 -30 -48 -102 -178
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Operating Revenue		 0.00 0.00 0.00 - - - 6.42 2.83 6.24 2.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.27 36 60 83 79 75 36 51 108 180
Selling, General & Admin Expense		 3.49 7.83 19 24 28 28 6.74 18 25 34
Research & Development Expense		 5.78 28 41 59 51 47 29 33 83 146
Total Other Income / (Expense), net		 -0.16 0.24 2.45 6.20 3.77 3.56 1.23 4.62 17 16
Interest & Investment Income		 0.00 0.24 2.45 6.20 3.77 3.56 1.15 4.76 17 16
Other Income / (Expense), net		 - - - - - - 0.08 -0.15 -0.62 -1.03
Basic Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Basic Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Weighted Average Basic & Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Cash Dividends to Common per Share		 - - - - - - - $0.00 $0.00 $0.00

Quarterly Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Consolidated Net Income / (Loss)		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Net Income / (Loss) Continuing Operations		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -65 -41
Total Pre-Tax Income 		-15 -11 -14 -18 -25 -28 -30 -32 -37 -65 -41
Total Operating Income		 -16 -13 -18 -22 -30 -32 -33 -35 -40 -70 -47
Total Gross Profit		 0.92 0.46 0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00
Total Revenue		 0.92 0.46 0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 17 13 19 24 32 33 34 35 41 70 47
Selling, General & Admin Expense		 8.72 4.63 5.64 6.00 6.53 6.83 7.34 8.87 8.20 9.93 12
Research & Development Expense		 7.96 8.78 13 18 26 26 27 26 32 60 35
Total Other Income / (Expense), net		 1.00 2.39 4.10 4.60 4.73 3.48 3.67 3.30 3.52 5.11 5.70
Interest & Investment Income		 1.03 2.44 4.22 4.71 4.45 3.99 3.79 3.40 3.66 5.27 6.27
Other Income / (Expense), net		 -0.03 -0.05 -0.13 -0.11 0.28 -0.51 -0.13 -0.14 -0.36 -0.41 -0.26
Basic Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Weighted Average Basic Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Diluted Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Weighted Average Diluted Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Weighted Average Basic & Diluted Shares Outstanding		 14.82M 29.35M 29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M
Cash Dividends to Common per Share		 - - $0.00 - - - $0.00 - - - $0.00

Annual Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.04 47 8.56 6.73 -6.92 73 7.79 117 -109 28
Net Cash From Operating Activities		 -6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Cash From Continuing Operating Activities		 -6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Income / (Loss) Continuing Operations		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Depreciation Expense		 0.01 0.38 0.88 1.84 1.98 2.02 0.03 0.07 0.10 0.11
Amortization Expense		 0.00 0.00 -0.19 -1.01 0.18 - -0.49 -1.14 -5.70 -5.85
Non-Cash Adjustments To Reconcile Net Income		 1.30 12 11 10 9.94 10 1.59 3.65 12 22
Changes in Operating Assets and Liabilities, net		 1.60 1.32 4.17 8.83 -1.19 -1.53 -1.72 4.11 -0.02 17
Net Cash From Investing Activities		 -0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Net Cash From Continuing Investing Activities		 -0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Purchase of Property, Plant & Equipment		 -0.14 -2.20 -7.67 -3.06 -0.40 -1.26 -0.14 -0.11 -0.11 -0.21
Purchase of Investments		 0.00 0.00 -84 -144 -96 -45 -62 -57 -414 -435
Sale and/or Maturity of Investments		 - 0.00 0.00 149 86 90 2.00 78 127 312
Net Cash From Financing Activities		 11 71 142 62 68 90 97 134 256 280
Net Cash From Continuing Financing Activities		 11 71 142 62 68 90 97 134 256 280
Issuance of Common Equity		 0.00 0.00 93 61 65 87 - 0.00 25 273
Other Financing Activities, net		 0.01 0.00 0.03 2.02 3.07 3.36 0.00 134 231 7.54
Cash Interest Paid		 - - - - - - 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 117 -25 197 -16 -280 -11 -13 3.12 43 -4.90 577
Net Cash From Operating Activities		 -9.99 -12 -15 -15 -21 -27 -28 -24 -31 -47 -29
Net Cash From Continuing Operating Activities		 -9.99 -12 -15 -15 -21 -27 -28 -24 -31 -47 -29
Net Income / (Loss) Continuing Operations		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Consolidated Net Income / (Loss)		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Depreciation Expense		 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Amortization Expense		 -0.26 -0.44 -0.43 -0.33 -2.25 -2.69 -1.79 -1.03 -2.24 -0.79 -1.17
Non-Cash Adjustments To Reconcile Net Income		 1.08 1.06 1.78 2.71 3.08 5.37 6.12 6.49 5.57 4.92 11
Changes in Operating Assets and Liabilities, net		 3.94 -1.93 -2.56 0.68 3.06 -1.72 -2.47 2.25 2.86 13 2.22
Net Cash From Investing Activities		 -12 -8.24 -5.51 1.17 -259 -23 15 26 -201 37 -134
Net Cash From Continuing Investing Activities		 -12 -8.24 -5.51 1.17 -259 -23 15 26 -201 37 -134
Purchase of Property, Plant & Equipment		 -0.07 -0.01 -0.03 -0.02 -0.03 -0.03 -0.02 -0.05 -0.01 -0.14 -0.01
Purchase of Investments		 -27 -26 -20 -6.81 -278 -108 -67 -33 -280 -55 -239
Sale and/or Maturity of Investments		 16 18 15 8.00 19 85 82 60 79 92 105
Net Cash From Financing Activities		 138 -4.87 218 -2.20 0.30 40 0.16 0.57 275 4.88 739
Net Cash From Continuing Financing Activities		 138 -4.87 218 -2.20 0.30 40 0.16 0.57 275 4.88 739
Issuance of Debt		 - - - - - - 0.00 - - - 678
Issuance of Common Equity		 - - 0.00 -2.24 - - 0.13 - 272 0.00 59
Other Financing Activities, net		 138 -4.87 230 0.05 0.30 0.48 0.03 0.57 2.06 4.88 2.94

Annual Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 54 157 162 162 190 83 179 374 531
Total Current Assets		 53 145 150 152 181 82 177 281 409
Cash & Equivalents		 51 58 65 58 132 15 132 23 51
Short-Term Investments		 0.00 84 81 91 45 60 41 252 353
Accounts Receivable		 - - - - - 4.70 0.29 0.81 0.05
Prepaid Expenses		 0.94 2.75 4.11 2.69 3.77 0.91 3.26 4.86 5.09
Plant, Property, & Equipment, net		 1.96 10 9.89 8.31 7.46 0.14 0.19 0.19 0.30
Total Noncurrent Assets		 0.00 1.78 1.78 1.78 1.78 0.94 1.77 93 121
Long-Term Investments		 - - - - - - 0.00 82 110
Other Noncurrent Operating Assets		 0.00 1.78 1.78 1.78 1.78 0.94 1.77 11 11
Total Liabilities & Shareholders' Equity		 54 157 162 162 190 83 179 374 531
Total Liabilities		 4.14 12 20 18 17 9.45 11 22 38
Total Current Liabilities		 4.14 10 14 11 11 8.23 9.63 18 31
Accounts Payable		 0.17 3.49 2.81 3.76 3.04 1.17 2.61 4.58 9.73
Accrued Expenses		 3.98 6.93 11 7.67 7.82 6.61 6.50 13 19
Current Deferred Revenue		 - - - - - 0.10 0.10 0.48 1.19
Other Current Liabilities		 - - - - 0.00 0.35 0.42 0.32 0.37
Total Noncurrent Liabilities		 0.00 1.25 6.21 6.28 6.40 1.23 0.90 3.08 6.79
Noncurrent Deferred Revenue		 - 1.25 6.21 6.28 6.40 0.79 0.74 1.91 5.77
Other Noncurrent Operating Liabilities		 0.00 - - - 0.00 0.44 0.17 1.17 1.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -42 146 141 144 173 -44 169 352 493
Total Preferred & Common Equity		 -42 146 141 144 173 -44 169 352 493
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -42 146 141 144 173 -44 169 352 493
Common Stock		 3.09 248 321 398 498 1.66 258 527 830
Retained Earnings		 -45 -103 -179 -254 -326 -46 -89 -174 -337
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 0.01 -0.02 -0.03 -0.16 0.05 0.11 0.49

Quarterly Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 83 79 192 382 369 354 349 326 577 1,247
Total Current Assets		 83 79 191 381 366 287 271 264 414 1,120
Cash & Equivalents		 49 63 157 330 314 34 10 13 56 628
Short-Term Investments		 30 15 33 47 47 247 253 244 347 484
Accounts Receivable		 - - 0.75 0.44 0.84 1.39 1.00 0.04 5.00 1.23
Prepaid Expenses		 2.91 1.05 0.83 3.01 3.31 3.68 6.77 6.18 6.21 7.42
Plant, Property, & Equipment, net		 0.00 0.00 0.20 0.20 0.19 0.19 0.19 0.21 0.19 0.27
Total Noncurrent Assets		 0.00 0.00 0.81 1.34 3.08 67 77 62 163 127
Long-Term Investments		 - - - - - 61 68 52 153 114
Other Noncurrent Operating Assets		 0.00 0.00 0.81 1.34 3.08 5.09 9.08 11 11 13
Total Liabilities & Shareholders' Equity		 83 79 192 382 369 354 349 326 577 1,247
Total Liabilities		 5.98 4.03 14 9.78 11 16 20 23 31 46
Total Current Liabilities		 5.98 4.03 13 8.96 10 16 17 20 24 38
Accounts Payable		 1.08 0.81 1.37 2.61 3.70 7.57 8.27 5.40 6.71 5.27
Accrued Expenses		 4.90 3.22 11 5.85 5.86 7.73 7.98 14 16 31
Current Deferred Revenue		 - - 0.10 0.10 0.10 0.10 0.48 0.48 0.95 1.49
Other Current Liabilities		 0.00 0.00 0.41 0.40 0.38 0.31 0.23 0.21 0.22 0.40
Total Noncurrent Liabilities		 0.00 0.00 1.00 0.82 0.71 0.64 3.02 2.90 7.14 7.29
Noncurrent Deferred Revenue		 - - 0.75 0.72 0.68 0.64 1.85 1.79 6.07 6.32
Other Noncurrent Operating Liabilities		 0.00 0.00 0.26 0.10 0.03 0.00 1.17 1.12 1.07 0.97
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 77 75 178 373 358 338 329 303 546 1,201
Total Preferred & Common Equity		 77 75 178 373 358 338 329 303 546 1,201
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 77 75 178 373 358 338 329 303 546 1,201
Common Stock		 509 509 257 476 479 483 532 539 819 1,579
Retained Earnings		 -431 -434 -79 -103 -121 -146 -204 -236 -272 -378
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.00 -0.00 -0.03 -0.04 0.68 0.27 0.10 0.16 -0.58

Annual Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Adjusted Shares Outstanding		 0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.74 -1.97 -1.55 -1.21 - - - -3.79
Growth Metrics		 - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -19.97% -20.23% -25.24%
Earnings before Interest and Taxes (EBIT)		 -9.27 -36 -60 -83 -79 -75 -30 -48 -102 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.26 -35 -59 -82 -77 -73 -30 -49 -108 -185
Valuation Ratios		 - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -24 -46 -50 -55 -53 -23 -31 -72 -108
Efficiency Ratios		 - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -1.25 3.08 -4.54 -4.93 -4.25 -1.83 -4.85 -4.49 -21
Increase / (Decrease) in Invested Capital		 0.00 -1.25 4.32 -7.61 -0.39 0.68 2.42 -3.01 0.36 -17
Book Value per Share		 $0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Tangible Book Value per Share		 $0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Total Capital		 0.00 50 146 141 144 173 74 169 352 493
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Capital Expenditures (CapEx)		 0.14 2.20 7.66 3.06 0.40 1.26 0.14 0.11 0.11 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.21 -7.67 -10 -8.74 -7.10 -1.68 -5.90 -13 -26
Debt-free Net Working Capital (DFNWC)		 0.00 48 135 136 140 170 74 168 262 379
Net Working Capital (NWC)		 0.00 48 135 136 140 170 74 168 262 379
Net Nonoperating Expense (NNE)		 2.94 10 16 19 20 19 7.68 9.83 14 38
Net Nonoperating Obligations (NNO)		 0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Total Depreciation and Amortization (D&A)		 0.01 0.38 0.69 0.83 2.16 2.02 -0.46 -1.07 -5.61 -5.74
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Basic Shares Outstanding		 149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Diluted Shares Outstanding		 149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Basic & Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Debt Service Ratios		 - - - - - - - - - -
Payout Ratios		 - - - - - - - - - -

Quarterly Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00
DEI Adjusted Shares Outstanding		 - - - - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.92 -0.98 -1.14 -1.50 -0.92
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -21.23% -91.29% 83.61% 92.26% 135.06% 190.15% 33.07% -100.00% -100.00% - -100.00%
EBITDA Growth		 -74.86% -166.78% -130.57% -89.32% -98.62% -161.25% -90.78% -59.39% -34.60% - -36.70%
EBIT Growth		 -92.56% -163.55% -133.53% -88.68% -87.58% -149.33% -85.32% -57.13% -37.24% - -40.52%
NOPAT Growth		 -90.93% -144.31% -132.25% -88.55% -89.73% -146.34% -85.93% -57.30% -34.74% - -40.26%
Net Income Growth		 -89.66% -154.09% -93.93% -58.05% -70.52% -169.24% -114.66% -79.64% -46.04% - -38.37%
EPS Growth		 57.53% 170.29% 93.33% 95.99% 80.42% -104.70% -51.85% -72.55% -31.08% - -3.66%
Operating Cash Flow Growth		 -161.02% -33.93% -45.28% -207.08% -112.84% -131.52% -84.93% -64.45% -43.67% - -4.44%
Free Cash Flow Firm Growth		 105.26% -133.55% -45.09% -78.23% -6,154.62% -274.84% -119.82% -30.42% 13.84% - 52.55%
Invested Capital Growth		 0.00% -164.34% -41.75% 16.73% 59.03% 7.34% 32.58% -141.66% -91.91% - -712.18%
Revenue Q/Q Growth		 -4.64% -50.54% 91.25% 113.16% 16.59% -38.95% -12.29% -100.00% 0.00% - -100.00%
EBITDA Q/Q Growth		 -34.16% 16.23% -36.86% -23.09% -40.74% -10.19% 0.06% -2.84% -18.85% - 32.20%
EBIT Q/Q Growth		 -33.51% 17.63% -38.16% -24.18% -32.73% -9.49% -2.69% -5.29% -15.93% - 33.10%
NOPAT Q/Q Growth		 -33.82% 17.79% -37.73% -24.43% -34.66% -6.74% -3.95% -5.27% -15.35% - 33.09%
Net Income Q/Q Growth		 -32.52% 28.45% -30.15% -28.07% -42.98% -12.97% -3.77% -7.18% -16.24% - 36.62%
EPS Q/Q Growth		 70.31% 527.51% -103.34% 5.56% -45.10% -2.70% -7.89% -7.32% -10.23% - 44.44%
Operating Cash Flow Q/Q Growth		 -111.20% -18.63% -26.04% 2.76% -46.39% -29.05% -0.68% 13.53% -27.89% - 38.58%
Free Cash Flow Firm Q/Q Growth		 105.08% -1,422.96% -85.13% -43.11% -72.74% 18.10% -8.56% 15.09% -14.11% - 63.62%
Invested Capital Q/Q Growth		 -284.38% 57.80% 10.29% 42.77% -89.11% 4.57% 34.73% -105.15% -50.17% - -13.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 -1,735.17% -2,938.95% -2,103.09% -1,214.49% -1,466.11% -2,646.23% -3,015.31% 0.00% 0.00% - 0.00%
Operating Margin		 -1,705.52% -2,835.01% -2,041.65% -1,191.84% -1,376.61% -2,406.94% -2,852.71% 0.00% 0.00% - 0.00%
EBIT Margin		 -1,708.87% -2,846.17% -2,056.06% -1,197.80% -1,363.67% -2,445.70% -2,863.46% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 -1,597.73% -2,311.38% -1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.39% - 100.75%
Interest Burden Percent		 93.50% 81.21% 76.51% 78.90% 84.99% 87.70% 88.62% 90.20% 91.00% - 86.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -15.09% -35.92% -22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -135.19% -61.28% -28.46% -22.04% -26.77% -55.11% -51.11% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 -126.40% -49.76% -21.77% -17.39% -22.75% -48.33% -45.29% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -15.09% -18.44% -22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70%
Return on Equity Simple (ROE_SIMPLE)		 -7.55% 0.00% -13.47% -15.82% -19.86% 0.00% -30.65% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -9.07 -12 -16 -21 -22 -23 -24 -28 -49 -33
NOPAT Margin		 -1,193.86% -1,984.51% -1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.93% -1.20% -0.55% -0.94% -1.59% -2.30% -1.77% -2.14% -1.91% - -1.06%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.37% - - - -6.34% -7.07% -8.07% -5.16% -9.87% -2.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 944.05% 1,013.57% 645.31% 321.90% 300.55% 515.01% 630.87% 0.00% 0.00% - 0.00%
R&D to Revenue		 861.47% 1,921.44% 1,496.34% 969.94% 1,176.06% 1,991.93% 2,321.84% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 1,805.52% 2,935.01% 2,141.65% 1,291.84% 1,476.61% 2,506.94% 2,952.71% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -13 -18 -22 -30 -32 -33 -35 -41 -70 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -13 -18 -23 -32 -35 -35 -36 -43 -71 -48
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.65 0.91 2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11
Price to Tangible Book Value (P/TBV)		 4.65 0.91 2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11
Price to Revenue (P/Rev)		 108.93 54.53 273.08 184.45 149.78 103.48 89.32 128.54 508.88 - 4,274.93
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 83.99 0.00 156.13 96.86 85.93 46.23 38.51 62.23 285.71 - 2,871.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 549.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.06 -1.03 -1.02 -1.01 -1.03 -1.02 -1.01 -1.01 -1.02 - -1.02
Leverage Ratio		 1.08 1.08 1.04 1.03 1.06 1.06 1.04 1.05 1.05 - 1.04
Compound Leverage Factor		 1.01 0.88 0.79 0.82 0.90 0.93 0.92 0.95 0.96 - 0.90
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 35.64 8.98 54.68 42.94 29.58 17.90 17.26 15.18 24.44 - 49.63
Noncontrolling Interest Sharing Ratio		 0.00% 48.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.64 18.43 42.52 36.46 18.30 15.22 15.99 13.12 17.35 - 29.25
Quick Ratio		 14.57 18.07 42.13 36.05 17.98 14.96 15.59 12.81 17.09 - 29.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.46 -6.06 -11 -16 -28 -23 -25 -21 -24 -32 -12
Operating Cash Flow to CapEx		 -15,372.31% -118,540.00% -46,690.63% -85,458.82% -85,068.00% -88,529.03% -115,125.00% -51,939.13% -611,100.00% - -288,560.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.08 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.01 - 0.00
Accounts Receivable Turnover		 0.00 1.13 0.00 0.00 5.01 11.33 9.09 10.61 0.78 - 0.78
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 17.28 0.00 0.00 27.95 32.90 33.80 23.54 13.31 - 3.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 322.51 0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 322.51 0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -11 -4.85 -4.35 -2.49 -4.71 -4.49 -2.93 -6.02 -9.03 -21 -24
Invested Capital Turnover		 -1.33 -0.85 -0.87 -1.50 -0.66 -1.34 -1.79 -1.10 -0.36 - -0.07
Increase / (Decrease) in Invested Capital		 -11 -3.01 -1.28 0.50 6.78 0.36 1.42 -3.53 -4.33 -17 -21
Enterprise Value (EV)		 639 -20 503 399 461 288 251 290 711 - 2,507
Market Capitalization		 829 154 880 760 804 645 583 599 1,267 - 3,732
Book Value per Share		 $2.94 $11.40 $12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01
Tangible Book Value per Share		 $2.94 $11.40 $12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01
Total Capital		 178 169 373 358 338 352 329 303 546 493 1,201
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -190 -174 -377 -361 -343 -357 -332 -309 -555 -514 -1,225
Capital Expenditures (CapEx)		 0.07 0.01 0.03 0.02 0.03 0.03 0.02 0.05 0.01 0.14 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -5.90 -5.07 -5.05 -9.34 -13 -9.18 -14 -13 -26 -30
Debt-free Net Working Capital (DFNWC)		 178 168 372 356 272 262 254 244 390 379 1,082
Net Working Capital (NWC)		 178 168 372 356 272 262 254 244 390 379 1,082
Net Nonoperating Expense (NNE)		 3.73 1.49 1.26 2.06 4.24 6.10 6.29 7.18 8.56 16 8.26
Net Nonoperating Obligations (NNO)		 -190 -174 -377 -361 -343 -357 -332 -309 -555 -514 -1,225
Total Depreciation and Amortization (D&A)		 -0.24 -0.42 -0.41 -0.31 -2.23 -2.66 -1.77 -1.00 -2.21 -0.76 -1.14
Debt-free, Cash-free Net Working Capital to Revenue		 -151.00% -208.70% -157.23% -122.61% -174.13% -205.12% -140.77% -297.73% -507.96% - -3,394.16%
Debt-free Net Working Capital to Revenue		 2,343.02% 5,938.43% 11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82%
Net Working Capital to Revenue		 2,343.02% 5,938.43% 11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Adjusted Weighted Average Basic Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Adjusted Diluted Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Adjusted Weighted Average Diluted Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 14.82M 29.35M 29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -9.07 -12 -16 -21 -22 -23 -24 -28 -49 -33
Normalized NOPAT Margin		 -1,193.86% -1,984.51% -1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 -1,597.73% -2,311.38% -1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise read on Dianthus Therapeutics’ four-year quarterly trends. The company has booked ongoing net losses and cash burn, but liquidity has improved in recent periods thanks to equity financing and investment activity. The bullets below capture the most notable positives, neutrals, and negatives in that order.

  • In Q3 2025, the company raised about $272.5 million via issuance of common equity, with net cash from financing activities around $274.5 million, providing a substantial liquidity runway.
  • Net cash from investing activities was positive in multiple quarters (about $37.2 million in both Q3 2025 and Q4 2025), driven by sale/maturity of investments.
  • Total assets grew to about $577.4 million by Q3 2025, and total equity stood around $546.5 million, indicating a larger asset and capital base to support ongoing R&D investment.
  • Cash and cash equivalents reached about $55.98 million at Q3 2025, contributing to improved near-term liquidity.
  • Total revenue remains minimal relative to expenses, with Q4 2025 revenue of about $0.87 million and many quarters showing near-zero revenue prior to expense ramps.
  • Research & development expenses represent a sizable ongoing cost (example: Q4 2025 RD expense about $59.90 million; Q3 2025 about $32.49 million; Q2 2025 about $26.25 million; Q1 2025 about $13.08 million).
  • Net cash from operating activities is typically negative across quarters, indicating ongoing cash burn before financing and investing activities.
  • In Q4 2025, net income dropped to -$64.43 million, highlighting a substantial quarterly loss.
  • Total operating expenses consistently outweigh revenue in many periods, contributing to deep pretax and net losses (for example, Q4 2025 total pretax income around -$64.71 million).
  • The company’s funding relies heavily on equity raises and financing activities, which may lead to shareholder dilution and increased cost of capital if fundraising needs persist. (Notable equity issuance occurred in Q3 2025.)
05/15/26 04:27 PM ETAI Generated. May Contain Errors.

Dianthus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dianthus Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Dianthus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$162.34 million in 2025, rising from -$9.43 million in 2016. The previous period was -$84.97 million in 2024. See Dianthus Therapeutics' forecast for analyst expectations on what's next for the company.

Dianthus Therapeutics' total operating income in 2025 was -$177.93 million, based on the following breakdown:
  • Total Gross Profit: $2.04 million
  • Total Operating Expenses: $179.97 million

Over the last 9 years, Dianthus Therapeutics' total revenue changed from $0.00 in 2016 to $2.04 million in 2025, a change of 203,600,000.0%.

Dianthus Therapeutics' total liabilities were at $37.52 million at the end of 2025, a 74.3% increase from 2024, and a 805.9% increase since 2017.

In the past 8 years, Dianthus Therapeutics' cash and equivalents has ranged from $15.37 million in 2022 to $132.33 million in 2023, and is currently $51.09 million as of their latest financial filing in 2025.

Over the last 9 years, Dianthus Therapeutics' book value per share changed from 0.00 in 2016 to 11.51 in 2025, a change of 1,150.8%.


Related Companies

Financial statements for NASDAQ:DNTH last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel